Monoclonal antibodies to the exon 18 encoded moiety of NCAM

Abstract

Aim: Exon 18 expression of NCAM has been recognized as a biomarker for small cell lung cancer (SCLC). To use this finding for an improved diagnosis of SCLC and personalized treatment of patients, techniques to identify and quantitate E18, the exon 18 encoded protein moiety of NCAM, are needed. We developed three monoclonal antibodies for this purpose.

Methods: The his-tagged E18 antigen was expressed in E. coli and, after purification, used to immunize mice. Hybridoma’s were isolated by standard procedures and tested for their reaction with E18.

Results: Three monoclonal antibodies, MUM-1, MUM-4 and MUM-6 were obtained. They reacted with E18 in western blots, with SCLC cell line NCI-H82, but not with unrelated his-tagged proteins. Only permeabilized NCI-H82 cells stained with the antibodies, confirming the intracellular position of E18. Next an enzyme-linked immunosorbent assay was developed using the earlier isolated monoclonal antibody MUMi-21B2, coated on the surface of microtiter wells as capture antibody and biotinylated MUM-6 as second antibody. Using streptavidin conjugated to horse radish peroxidase a linear dose response curve to his-tagged E18 antigen was obtained between 0 and 5 µg/mL with a sensitivity of at least 0.5 µg/mL or 50 ng/well.

Conclusion: Four monoclonal antibodies are available to be used in assays for the identification and quantification of SCLC biomarker E18. This will enable the development of liquid biopsies to follow the tumor load in patients.

Keywords

Small cell lung cancer / tumor biomarker / monoclonal antibodies / NCAM exon 18

References

[1] Gazdar AF,Minna JD.Small-cell lung cancer: what we know, what we need to know and the path forward..Nat Rev Cancer2017;17:765

[2] van Meerbeeck JP,De Ruysscher DK.Small-cell lung cancer..Lancet2011;378:1741-55

[3] Rudin CM,Hann CL,Movsas B.Treatment of small-cell lung cancer: American society of clinical oncology endorsement of the American college of chest physicians guideline..J Clin Oncol2015;33:4106-11

[4] Lally BE,Blackstock AW,Perry MC.Small cell lung cancer: have we made any progress over the last 25 years?.Oncol2007;12:1096-104

[5] Vander Borght A,Broers JLV,Falkenberg FW.The 180 splice variant of NCAM-containing exon 18-is specifically expressed in small cell lung cancer cells..Transl Lung Cancer Res2018;7:376-88 PMCID:PMC6037973

[6] Kim JY,Ro JY.Recent updates on grading and classification of neuroendocrine tumors..Ann Diagn Pathol2017;29:11-6

[7] Rekhtman N.Neuroendocrine tumors of the lung: an update..Arch Pathol Lab Med2010;134:1628-38

[8] Travis WD.Advances in neuroendocrine lung tumors..Ann Oncol.2010;21 Suppl 7:vii65-71

[9] Lane RD.A short-duration polyethylene glycol fusion technique for increasing production of monoclonal antibody-secreting hybridomas..J Immunol Methods1985;81:223-8

[10] Lehman JM,Massion PP.Immunotherapy and targeted therapy for small cell lung cancer: there is hope..Curr Oncol Rep2017;19:49

[11] Mamdani H,Jalal SI.Novel therapies in small cell lung cancer..Transl Lung Cancer Res2015;4:533-44 PMCID:PMC4630526

[12] Hendriks LEL,Reck M.Prospects of targeted and immune therapies in SCLC..Expert Rev Anticancer Ther2018;28:1-17

[13] Almodovar K,Meador CB,York S.Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse..J Thorac Oncol2018;13:112-23 PMCID:PMC5827950

[14] Foy V,Faivre-Finn C,Blackhall F.The clinical utility of circulating tumour cells in patients with small cell lung cancer..Transl Lung Cancer Res2017;6:409-17 PMCID:PMC5583068

[15] Choi DS,Kim YK.Proteomics of extracellular vesicles: exosomes and ectosomes..Mass Spectrom Rev2015;34:474-90

[16] Kaufmann O,Dietel M.Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections..Hum Pathol1997;28:1373-8

[17] Kibbelaar RE,Michalides RJ,Vanderschueren RG.Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma..Eur J Cancer1991;27:431-5

[18] Greening DW,Ji H,Simpson RJ.A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods..Methods Mol Biol2015;1295:179-209

[19] Boerman OC,Broers JL,Ramaekers FC.Biodistribution of a monoclonal antibody (RNL-1) against the neural cell adhesion molecule (NCAM) in athymic mice bearing human small-cell lung-cancer xenografts..Int J Cancer1991;48:457-62

[20] Schol DJ,van der Gugten AA,Hilgers J.Monoclonal antibody 123C3, identifying small cell carcinoma phenotype in lung tumours, recognizes mainly, but not exclusively, endocrine and neuron-supporting normal tissues..Int J Cancer Suppl1988;2:34-40

[21] Gerardy-Schahn R,Ledermann J.Topography of NCAM antigenic epitopes recognized by SCLC-cluster-1 antibodies. A consensus view..Int J Cancer Suppl1994;8:27-9